- Home
- BKE vs KYMR Comparison
BKE vs KYMR Comparison
Compare BKE & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKE
- KYMR
- Stock Information
- Founded
- BKE 1948
- KYMR 2015
- Country
- BKE United States
- KYMR United States
- Employees
- BKE N/A
- KYMR N/A
- Industry
- BKE Clothing/Shoe/Accessory Stores
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- BKE Consumer Discretionary
- KYMR Health Care
- Exchange
- BKE Nasdaq
- KYMR Nasdaq
- Market Cap
- BKE 1.8B
- KYMR 1.8B
- IPO Year
- BKE 1992
- KYMR 2020
- Fundamental
- Price
- BKE $37.01
- KYMR $30.77
- Analyst Decision
- BKE Hold
- KYMR Buy
- Analyst Count
- BKE 1
- KYMR 13
- Target Price
- BKE $41.00
- KYMR $56.69
- AVG Volume (30 Days)
- BKE 448.6K
- KYMR 762.3K
- Earning Date
- BKE 05-23-2025
- KYMR 05-09-2025
- Dividend Yield
- BKE 10.83%
- KYMR N/A
- EPS Growth
- BKE N/A
- KYMR N/A
- EPS
- BKE 3.89
- KYMR N/A
- Revenue
- BKE $1,217,689,000.00
- KYMR $47,072,000.00
- Revenue This Year
- BKE $0.03
- KYMR $16.24
- Revenue Next Year
- BKE N/A
- KYMR $22.41
- P/E Ratio
- BKE $9.26
- KYMR N/A
- Revenue Growth
- BKE N/A
- KYMR N/A
- 52 Week Low
- BKE $33.12
- KYMR $19.45
- 52 Week High
- BKE $54.25
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- BKE 57.13
- KYMR 51.09
- Support Level
- BKE $34.95
- KYMR $28.34
- Resistance Level
- BKE $36.21
- KYMR $35.98
- Average True Range (ATR)
- BKE 0.94
- KYMR 2.19
- MACD
- BKE 0.38
- KYMR 0.02
- Stochastic Oscillator
- BKE 94.70
- KYMR 50.31
About BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to better-priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.